Biotech

All Articles

AN 2 fifty percents roll call, quits stage 3 trial after records disappoint

.AN2 Therapeutics is rethinking its own company in feedback to dull midphase data, promising to lay ...

Merck pays for $700M for bispecific, snooping autoimmune position and opportunity to challenge Amgen in cancer cells

.Merck &amp Co. is spending $700 thousand upfront to test Amgen in a blood cancer cells market. The ...

Gilead pays out J&ampJ $320M to leave licensing deal for seladelpar

.Along With Gilead Sciences about to an FDA decision for its own liver condition medication seladelp...

' All hands on deck' at Lilly as peers target being overweight market

.CEO David Ricks can easily view the business establishing camping tents at basecamp behind Eli Lill...

Entero laying off personnel, abandoning office and also stopping R&ampD

.Bed Liquidators has switched Entero Rehabs white as a sheet. The collector purchased Entero to repa...

Exelixis goes down ADC after choosing it is actually no match for Tivdak

.Exelixis is actually giving up on its cells variable (TF)- targeting antibody-drug conjugate after ...

Relay loses interest in SHP2 inhibitor after Genentech leaves

.Three weeks after Roche's Genentech device ignored an SHP2 prevention deal, Relay Therapeutics has ...

Stoke's Dravet syndrome med discharged of predisposed scientific grip

.Stoke Therapies' Dravet disorder drug has actually been freed from a predisposed grip, getting rid ...

Fierce Biotech's Gabrielle Masson presents Ferocious 15 at NYSE

.Fierce Biotech Associate Publisher Gabrielle Masson provided the 2024 training class of Tough 15 ch...

Novo Nordisk centers once-monthly GLP-1\/ GIP agonist, MASH possibility

.Novo Nordisk has actually axed its own once-monthly double GLP-1/ GIP receptor agonist, ending (PDF...